BELLINI, STEFANIA
 Distribuzione geografica
Continente #
NA - Nord America 217
EU - Europa 128
AS - Asia 78
AF - Africa 8
Totale 431
Nazione #
US - Stati Uniti d'America 217
VN - Vietnam 28
GB - Regno Unito 25
CN - Cina 24
DE - Germania 20
IT - Italia 20
SE - Svezia 17
UA - Ucraina 16
SG - Singapore 14
IN - India 11
FR - Francia 7
RU - Federazione Russa 7
BE - Belgio 4
EE - Estonia 4
IE - Irlanda 4
TG - Togo 4
BG - Bulgaria 3
SC - Seychelles 2
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
HK - Hong Kong 1
NG - Nigeria 1
Totale 431
Città #
Chandler 30
Dong Ket 28
Southend 20
Ashburn 17
Fairfield 17
Ann Arbor 16
Houston 12
Jacksonville 12
Singapore 12
Cambridge 11
Seattle 11
Wilmington 11
Woodbridge 11
Santa Clara 8
Boardman 6
New York 6
Princeton 6
Bologna 5
Padova 5
Brussels 4
Dublin 4
Lomé 4
Zhengzhou 4
Berlin 3
Bremen 3
Des Moines 3
Hyderabad 3
Redwood City 3
Saint Petersburg 3
Sofia 3
Westminster 3
Frankfurt am Main 2
Guangzhou 2
Jinan 2
Leawood 2
Mahé 2
Milan 2
Monmouth Junction 2
Mülheim 2
Nanchang 2
Nanjing 2
Shenyang 2
Abeokuta 1
Abidjan 1
Beijing 1
Changsha 1
Chicago 1
Edinburgh 1
Fremont 1
Hebei 1
Hong Kong 1
London 1
Los Angeles 1
Medford 1
Moscow 1
Napoli 1
Pune 1
Qualiano 1
Shanghai 1
Shaoxing 1
St Louis 1
Tallinn 1
Verona 1
Totale 327
Nome #
Bis-guanylhydrazone diimidazo[1,2-a:1,2-c]pyrimidine as a novel and specific G-quadruplex binding motif 150
SUBSTITUTED E-3-(3-INDOLYLMETHYLENE)1,3-DIHYDROINDOL-2-ONES WITH ANTITUMOR ACTIVITY. IN-DEPTH STUDY OF THE EFFECT ON GROWTH OF BREAST CANCER CELLS. 148
Substituted E-3-(3-Indolylmethylene)-1,3-dihydroindol-2-ones with Antitumor Activity. In Depth Study of the Effect on Growth of Breast Cancer Cells 138
Totale 436
Categoria #
all - tutte 1.042
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.042


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202071 0 0 0 0 0 13 11 14 10 12 7 4
2020/202186 14 4 4 4 3 8 1 3 6 4 3 32
2021/202263 5 2 0 4 7 6 1 4 2 7 14 11
2022/202383 6 16 2 18 13 4 1 7 10 0 6 0
2023/202424 1 5 1 1 2 11 0 1 0 1 0 1
2024/202541 4 6 10 2 13 6 0 0 0 0 0 0
Totale 436